Lu, X. Kia, L. Wang, et al. Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro.
Cancer Immunol Immunother, 55 , pp. Ahn, S. Bae, K. Lee, J. Lee, S. Namkoong, H. Chun, et al. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.
Gynecol Oncol, 92 , pp. Bae, J. Namkoong, J. Yoo, Y. Seo, et al. Anti-cancer effect of adenovirus p53 on human cervical cancer cell growth in vitro and in vivo. Int J Gynecol Cancer, 14 , pp. Ganjavi, M. Gee, A. Narendran, N. Parkinson, M. Krishnamoorthy, M. Freedman, et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.
Cancer Gene Ther, 13 , pp. Swisher, J. Curr Oncol Rep, 4 , pp. Inoue, K. Shiraki, K. Murata, K. Sugimoto, T. Kawakita, Y. Yamaguchi, et al. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Int J Mol Med, 14 , pp. Yang, C. Cirielli, M. Capogrossi, A. Adenovirusmediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res, 55 , pp. The role of p53 in chemosensitivity and radiosensitivity. Oncogene, 22 , pp. Expert Opin Biol Ther, 6 , pp. Ma, H. Shimada, K. Hiroshima, Y. Tada, N. Suzuki, M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.
Drug Des Devel Ther, 2 , pp. Shi, D. Curr Opin Mol Ther, 11 , pp. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther, 16 , pp.
Drugs R. Zhang, S. Liu, C. Liang, H. Adenovirus-mediated Rb gene transfect for head and neck cancer. Zhang, A. Multani, J. Zhou, J. Shay, D. McConkey, L. Dong, et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells.
Cancer Res, 63 , pp. Zhou, X. Zhang, F. Ashoori, D. McConkey, M. Knowles, L. Early RBproduced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation. Cancer Gene Ther, 16 , pp. Eberle, L. Fecker, A. Hossini, B. Kurbanov, H. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.
Exp Dermatol, 17 , pp. Kagaya, Y. Nakamoto, Y. Sakai, T. Tsuchiyama, H. Yagita, N. Mukaida, et al. Tu, P. Liston, J. Cui, M. Lin, X. Jiang, Y. Yang, et al. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer.
Int J Cancer, , pp. Dachs, J. Tupper, G. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs, 16 , pp. Wang, X. Lu, D. Chen, S. Li, L. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J Gastroenterol, 10 , pp.
Chen, D. Curr Pharm Des, 8 , pp. Maatta, H. Samaranayake, J. Pikkarainen, T. Wirth, S. Curr Gene Ther, 9 , pp. Huang, P. Pu, Z. Xia, Y. J Neurooncol, 82 , pp. Huang, W. Tan, W. Zhu, Z. Lethal effect of adenovirus-mediated HSV-TK gene in combination with hydroxycamptothecin on human bladder cancer in vitro. Luo, J. Li, Y. Niu, L.
Adenovirus-mediated double suicide gene selectively kills gastric cancer cells. Asian Pac J Cancer Prev, 13 , pp. Maatta, A. Tenhunen, T. Pasanen, O. Pellinen, K. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol, 24 , pp. Immonen, M. Vapalahti, K. Hurskainen, A. Sandmair, R. Vanninen, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.
Mol Ther, 10 , pp. Sviatchenko, M. Tarasova, S. Netesov, P. Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives. Mol Biol Mosk , 46 , pp. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther, 5 , pp. Wildner, D. Hoffmann, C. Jogler, K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.
Cancer Gene Ther, 10 , pp. Alemany, C. Balague, D. Nat Biotechnol, 18 , pp. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci, , pp.
Vasey, L. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, et al. J Clin Oncol, 20 , pp. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, et al. Phase II trial of intratumoral administration of ONYX, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol, 19 , pp. Dias, I. Liikanen, K. Guse, J. Foloppe, M. Sloniecka, I. Diaconu, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Clin Cancer Res, 16 , pp. CCR Medline. Yu, H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets, 7 , pp. Xia, J. Chang, L. Zhang, W. Jiang, Z. Guan, J. Liu, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus H combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.
Ai Zheng, 23 , pp. Wei, H. Wang, H. Qiu, P. Ren, et al. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors. Cancer Biother Radiopharm, 25 , pp. Dias, K. Guse, P. Nokisalmi, M. Eriksson, D. Chen, I. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur J Cancer, 46 , pp. Fueyo, C.
Gomez-Manzano, R. Alemany, P. Lee, T. McDonnell, P. Mitlianga, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19 , pp. Heise, T. Hermiston, L.
Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med, 6 , pp. Tuting, W. Storkus, M. Gene-based strategies for the immunotherapy of cancer. J Mol Med Berl , 75 , pp. Barajas, G. Mazzolini, G. Bilbao, I. Narvaiza, V. Schmitz, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin Hepatology, 33 , pp.
Slos, M. De, P. Leroy, C. Rousseau, B. Cancer Gene Ther, 8 , pp. Nakamura, M. Iwahashi, M. Nakamori, K. Ueda, I. Matsuura, K. Noguchi, et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res, 8 , pp.
Volpert, K. Dameron, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14 , pp. Ribatti, A. Vacca, M. The discovery of angiogenic factors: a historical review. Gen Pharmacol, 35 , pp.
Denekamp, A. Dasu, A. Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?. Adv Enzyme Regul, 38 , pp. Liang, J. Wu, J. Tan, M. Ke, R. Protein Expr Purif, 56 , pp. Adhim, X. Lin, W. Huang, N. Morishita, T. Nakamura, H. Yasui, et al. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
Lin, H. Huang, S. Li, H. Cao, et al. A phase I clinical trial of an adenovirus-mediated endostatin gene E10A in patients with solid tumors. Cancer Biol Ther, 6 , pp. Jin, R.
Bookstein, K. Wills, J. Avanzini, V. Tsai, D. LaFace, et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. He, G. Xue, L. There followed a productive period on the dynamics of RSV infection. Its epidemiology in chickens is described. The coat determines the antigenicity, host range, and maturation rate of RSV. This was the bridge that joined the biological era to the molecular era. Its relation to oncogenes and human cancer is discussed.
0コメント